PP73 Evaluating Alignment Between FDA Accelerated Approvals And EMA, MHRA, And NICE Recommendations
Mouna Dardouri, Michael J DiStefano · 2025
Read PP73 Evaluating Alignment Between FDA Accelerated Approvals And EMA, MHRA, And NICE Recommendations by Mouna Dardouri, Michael J DiStefano (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12768826.txt.
Description
Mouna Dardouri and Michael DiStefano check in 2025 how well fast-track drug approvals in the United States align with calls by European and British bodies. Accelerated approval speeds patient access but demands later proof trials. Whether peer regulators agree on converted drugs was unmapped across all disease areas.
The study tracks drug-use pairs granted fast approval and converted to full approval from 2020 to 2024. In all, 115 pairs win fast approval in that window. Eight are later withdrawn, and 78 remain pending at study end. Decisions on market entry and coverage are pulled from agency documents. Alignment rates by disease class reveal where world regulators converge and where they part ways.
Catalog record
| CREATOR | Mouna Dardouri, Michael J DiStefano |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |